

Docetaxel CHAARTED

PRELIMINARY SCORE

CURATIVE

NON-CURATIVE

ADJUSTMENTS

Quality of life

No benefit observed

Serious and disabling adverse effects

Other adjustments

Docetaxel CHAARTED

SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers

Therapeutic Indication: In combination with androgen-deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer.

Experimental Arm: Docetaxel + ADT (androgen deprivation therapy)

Control Arm: ADT

